Dicerna Pharmaceuticals Inc. has agreed to $25 million worth of cash and stock to settle a long-running legal spat with competitor Alnylam Pharmaceuticals Inc., which had sought damages in excess of $100 million against it. News of the settlement sent Dicerna's shares (NASDAQ:DRNA) briefly more than 40 percent higher Friday, before ending the day at $12.01, up $1.82.